Sarah Kennedy, founder and CEO of Calocurb, joins Tony to discuss new clinical research showing that GLP-1 weight loss medications may cause significant muscle loss alongside fat loss, and how Calocurb, a natural GLP-1 activator backed by 15 years of New Zealand government-funded science, offers an alternative for those seeking fat loss without the muscle preservation concerns associated with prescription GLP-1 injections.